Ирина Вячеславовна Сильнова
Ирина Вячеславовна Сильнова has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Elena N. Basargina
National Medical Research Center of Children's Health
6 shared publications - Kirill Victorovich Savostyanov
National Medical Research Center for Children’s Health, Moscow, Russia
6 shared publications - Leila A. Gandaeva
National Medical Research Center for Children’s Health
6 shared publications - Aleksander Alekseevich Pushkov
National Medical Research Center for Children’s Health, Ministry of Health of Russian Federation
4 shared publications - Nataliya A. Sdvigova
National Medical Research Center of Children's Health
3 shared publications - Olga P. Zharova
National Medical Research Center for Children’s Health
3 shared publications
Latest Publications
- Open Access
- 5 July 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (2) , 88-99
Clinical and Genetic Characteristics of 114 Russian Children with a Monogenic Non-Sarcomeric Hypertrophic Cardiomyopathy Phenotype
Introduction . In children, cardiomyopathies with a morphofunctional phenotype similar to sarcomeric hypertrophic cardiomyopathies are associated with various syndromes and diseases in almost half of cases, and for some of these nosologies, etiopathogenetic therapy is currently possible. Aim : to determine the clinical, laboratory-instrumental, and genetic characteristics of the most common monogenic orphan diseases accompanied by a hypertrophic cardiomyopathy phenotype in children. Methods . The study included 335 patients diagnosed with hypertrophic cardiomyopathies who were regularly followed up at the cardiology department of the National Medical Research Center for Children’s Health, Ministry of Health of the Russian Federation, from 2014 to 2025. All patients underwent molecular genetic analysis of target genomic regions containing 420 genes, in which pathogenic variants have been described in patients with a hypertrophic cardiomyopathy phenotype, using high-throughput sequencing. According to the study design, a comparative analysis of the course of the hypertrophic cardiomyopathy phenotype in children was performed based on the etiological cause—within the framework of inherited metabolic disorders, due to mitochondrial pathology, and RAS-pathy syndromes (n=114). Results . Molecular genetic examination of patients with a hypertrophic cardiomyopathy phenotype verified rare hereditary diseases, including mitochondrial disorders (causal variants in mitochondrial or nuclear DNA), Pompe disease, Danon disease, PRKAG2 syndrome, and various RAS-pathy syndromes. A comparative characterization was performed, showing a high frequency of the hypertrophic cardiomyopathy phenotype in children with early-onset RAS-pathy syndromes. Myocardial hypertrophy exceeding 30 mm was rarely recorded; a symmetric form of the disease was significantly more common in mitochondrial pathology, asymmetric in RAS-pathy syndromes, and biventricular in inherited metabolic disorders. In addition to myocardial hypertrophy, patients with inherited metabolic disorders and mitochondrial pathology exhibited left ventricular dilation and reduced contractility. Patients with RAS-pathy syndromes had more pronounced (grade II–III) mitral regurgitation and a high frequency of pulmonary valve insufficiency (30.8%). Wolff–Parkinson–White syndrome (WPW) phenomenon and nonsustained supraventricular tachycardia were recorded in inherited metabolic disorders. In mitochondrial pathology, an increase in creatine phosphokinase-MB (CK-MB) with normal CK levels was noted; in inherited metabolic disorders, high values of CK, lactate dehydrogenase, and transaminases were observed. No significant difference in the frequency of elevation or in NT-proBNP levels was found between patients. Surgical treatment in the form of septal myectomy was performed mainly in RAS-pathy syndromes (23; 20%) and in one case of PRKAG2 syndrome. During the follow-up period, 17 (14.7%) children died; heart transplantation and cardioverter defibrillator implantation were performed in patients with Danon disease and PRKAG2 syndrome. Conclusion . Myocardial hypertrophy in children may be the first symptom of numerous non-sarcomeric monogenic diseases with varying etiologies, prognoses, and treatments. Understanding the features of the hypertrophic cardiomyopathy phenotype course allows for differential diagnosis before molecular genetic results are available and enables timely treatment adjustments. The introduction of high-throughput sequencing into clinical practice allows simultaneous analysis of a large number of genes causing the hypertrophic cardiomyopathy phenotype, opening new possibilities for early diagnosis of rare diseases in children and providing a better evidence base for further research.
- 5 July 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (2) , 88-99
Open AccessClinical and Genetic Characteristics of 114 Russian Children with a Monogenic Non-Sarcomeric Hypertrophic Cardiomyopathy Phenotype
Introduction . In children, cardiomyopathies with a morphofunctional phenotype similar to sarcomeric hypertrophic cardiomyopathies are associated with various syndromes and diseases in almost half of cases, and for some of these nosologies, etiopathogenetic therapy is currently possible. Aim : to determine the clinical, laboratory-instrumental, and genetic characteristics of the most common monogenic orphan diseases accompanied by a hypertrophic cardiomyopathy phenotype in children. Methods . The study included 335 patients diagnosed with hypertrophic cardiomyopathies who were regularly followed up at the cardiology department of the National Medical Research Center for Children’s Health, Ministry of Health of the Russian Federation, from 2014 to 2025. All patients underwent molecular genetic analysis of target genomic regions containing 420 genes, in which pathogenic variants have been described in patients with a hypertrophic cardiomyopathy phenotype, using high-throughput sequencing. According to the study design, a comparative analysis of the course of the hypertrophic cardiomyopathy phenotype in children was performed based on the etiological cause—within the framework of inherited metabolic disorders, due to mitochondrial pathology, and RAS-pathy syndromes (n=114). Results . Molecular genetic examination of patients with a hypertrophic cardiomyopathy phenotype verified rare hereditary diseases, including mitochondrial disorders (causal variants in mitochondrial or nuclear DNA), Pompe disease, Danon disease, PRKAG2 syndrome, and various RAS-pathy syndromes. A comparative characterization was performed, showing a high frequency of the hypertrophic cardiomyopathy phenotype in children with early-onset RAS-pathy syndromes. Myocardial hypertrophy exceeding 30 mm was rarely recorded; a symmetric form of the disease was significantly more common in mitochondrial pathology, asymmetric in RAS-pathy syndromes, and biventricular in inherited metabolic disorders. In addition to myocardial hypertrophy, patients with inherited metabolic disorders and mitochondrial pathology exhibited left ventricular dilation and reduced contractility. Patients with RAS-pathy syndromes had more pronounced (grade II–III) mitral regurgitation and a high frequency of pulmonary valve insufficiency (30.8%). Wolff–Parkinson–White syndrome (WPW) phenomenon and nonsustained supraventricular tachycardia were recorded in inherited metabolic disorders. In mitochondrial pathology, an increase in creatine phosphokinase-MB (CK-MB) with normal CK levels was noted; in inherited metabolic disorders, high values of CK, lactate dehydrogenase, and transaminases were observed. No significant difference in the frequency of elevation or in NT-proBNP levels was found between patients. Surgical treatment in the form of septal myectomy was performed mainly in RAS-pathy syndromes (23; 20%) and in one case of PRKAG2 syndrome. During the follow-up period, 17 (14.7%) children died; heart transplantation and cardioverter defibrillator implantation were performed in patients with Danon disease and PRKAG2 syndrome. Conclusion . Myocardial hypertrophy in children may be the first symptom of numerous non-sarcomeric monogenic diseases with varying etiologies, prognoses, and treatments. Understanding the features of the hypertrophic cardiomyopathy phenotype course allows for differential diagnosis before molecular genetic results are available and enables timely treatment adjustments. The introduction of high-throughput sequencing into clinical practice allows simultaneous analysis of a large number of genes causing the hypertrophic cardiomyopathy phenotype, opening new possibilities for early diagnosis of rare diseases in children and providing a better evidence base for further research.
- Open Access
- 29 April 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (1) , 60-68
Dilated cardiomyopathy in the structure of a familial form of TOP3A-related Bloom-like syndrome
Bloom-like syndrome is a rare autosomal recessive disorder caused by nucleotide variants in the TOP3A gene. It is characterized by clinical manifestations similar to Bloom syndrome, including a characteristic facial phenotype and physical development delay, but diff ers in the more frequent development of a dilated cardiomyopathy. These syndromes belong to the group of hereditary diseases associated by impaired DNA repair. Given the existence of isolated clinical cases with a predominant description of characteristic physical development delay, a detailed description of the course of dilated cardiomyopathy is signifi cant for understanding the disease and optimizing medical treatment. Here is a description of the clinical course and features of the child’s management with a homozygous mutation c.2264_2265delinsT in the TOP3A gene, examined at the cardiology department of the National Medical Research Center of Children’s Health of the Ministry Health of the Russian Federation. An analysis of anamnesis data, including family history, results of clinical, laboratory, instrumental diagnostic methods, and molecular genetic testing performed using Sanger direct sequencing technology, was conducted. A literature review of patients with mutations in the TOP3A gene was conducted. The presented clinical case demonstrates the importance of timely diagnosis of the disease, the high frequency of cardiac manifestations, particularly the steadily progressive and fatal course of dilated cardiomyopathy. In childhood, dilated cardiomyopathy can be a dominant and life-threatening manifestation of TOP3A -associated Bloom-like syndrome. Given the risk of a sudden and aggressive course of dilated cardiomyopathy, identifying mutations in the TOP3A gene in children with physical development delay and a characteristic «bird-like» facies has important prognostic value. Improving the prognosis requires early diagnosis, including prenatal diagnosis in high-risk families, the development of pathogenetic therapy, and a multidisciplinary approach to patient management.
- 29 April 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (1) , 60-68
Open AccessDilated cardiomyopathy in the structure of a familial form of TOP3A-related Bloom-like syndrome
Bloom-like syndrome is a rare autosomal recessive disorder caused by nucleotide variants in the TOP3A gene. It is characterized by clinical manifestations similar to Bloom syndrome, including a characteristic facial phenotype and physical development delay, but diff ers in the more frequent development of a dilated cardiomyopathy. These syndromes belong to the group of hereditary diseases associated by impaired DNA repair. Given the existence of isolated clinical cases with a predominant description of characteristic physical development delay, a detailed description of the course of dilated cardiomyopathy is signifi cant for understanding the disease and optimizing medical treatment. Here is a description of the clinical course and features of the child’s management with a homozygous mutation c.2264_2265delinsT in the TOP3A gene, examined at the cardiology department of the National Medical Research Center of Children’s Health of the Ministry Health of the Russian Federation. An analysis of anamnesis data, including family history, results of clinical, laboratory, instrumental diagnostic methods, and molecular genetic testing performed using Sanger direct sequencing technology, was conducted. A literature review of patients with mutations in the TOP3A gene was conducted. The presented clinical case demonstrates the importance of timely diagnosis of the disease, the high frequency of cardiac manifestations, particularly the steadily progressive and fatal course of dilated cardiomyopathy. In childhood, dilated cardiomyopathy can be a dominant and life-threatening manifestation of TOP3A -associated Bloom-like syndrome. Given the risk of a sudden and aggressive course of dilated cardiomyopathy, identifying mutations in the TOP3A gene in children with physical development delay and a characteristic «bird-like» facies has important prognostic value. Improving the prognosis requires early diagnosis, including prenatal diagnosis in high-risk families, the development of pathogenetic therapy, and a multidisciplinary approach to patient management.
- Open Access
- 31 January 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 6 (4) , 221-227
Oxidative phosphorylation deficiency type 10 is a rare cause of hypertrophic cardiomyopathy
Introduction. Oxidative phosphorylation deficiency, type 10 is a rare variant of mitochondrial disease characterized by lactate acidosis, damage to the cardiovascular and central nervous systems. Given the variability of phenotype-genotypic correlations, a detailed description of the clinical picture of the disease is important for understanding possible variants of the course of the disease.Materials and methods. During a molecular genetic study of three hundred fourteen pediatric patients with a guiding diagnosis of hypertrophic cardiomyopathy, one patient with a deficiency of oxidative phosphorylation, type 10, was identified.Results. The analysis of the nature of the disease course during the period of dynamic follow-up (over 3 years) was carried out.Conclusion. Deficiency of oxidative phosphorylation, type 10, is a rare cause of the hypertrophic phenotype of cardiomyopathy. Isolated cases of this disease have been described in the literature, which makes the observation significant for a wide range of specialists (pediatricians, neurologists, cardiologists).Compliance with ethical standards. Voluntary informed consent was obtained from the patient’s legal representative for the publication of material related to the patient in Russian and foreign medical periodicals (dated October 1, 2024). Contribution:Shifova N.A. — concept and design of research, collection and processing of material, writing, editing;Gandaeva L.A. — editing;Globa O.V. — editing;Silnova I.V. — editing;Davydova Yu.I. — editing;Basargina E.Y. — editing;Savostyanov K.V. — the concept and design of the study.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: August 18, 2025Accepted:September 30, 2025Published: January 31, 2026
- 31 January 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 6 (4) , 221-227
Open AccessOxidative phosphorylation deficiency type 10 is a rare cause of hypertrophic cardiomyopathy
Introduction. Oxidative phosphorylation deficiency, type 10 is a rare variant of mitochondrial disease characterized by lactate acidosis, damage to the cardiovascular and central nervous systems. Given the variability of phenotype-genotypic correlations, a detailed description of the clinical picture of the disease is important for understanding possible variants of the course of the disease.Materials and methods. During a molecular genetic study of three hundred fourteen pediatric patients with a guiding diagnosis of hypertrophic cardiomyopathy, one patient with a deficiency of oxidative phosphorylation, type 10, was identified.Results. The analysis of the nature of the disease course during the period of dynamic follow-up (over 3 years) was carried out.Conclusion. Deficiency of oxidative phosphorylation, type 10, is a rare cause of the hypertrophic phenotype of cardiomyopathy. Isolated cases of this disease have been described in the literature, which makes the observation significant for a wide range of specialists (pediatricians, neurologists, cardiologists).Compliance with ethical standards. Voluntary informed consent was obtained from the patient’s legal representative for the publication of material related to the patient in Russian and foreign medical periodicals (dated October 1, 2024). Contribution:Shifova N.A. — concept and design of research, collection and processing of material, writing, editing;Gandaeva L.A. — editing;Globa O.V. — editing;Silnova I.V. — editing;Davydova Yu.I. — editing;Basargina E.Y. — editing;Savostyanov K.V. — the concept and design of the study.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: August 18, 2025Accepted:September 30, 2025Published: January 31, 2026
- Open Access
- 27 June 2025
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 28 (3) , 223-230
Chronic heart failure in children: etiology, pathogenesis, clinical picture and diagnosis
Introduction. Chronic heart failure (CHF) is a threatening complication of cardiovascular diseases or damage in other pathological processes. CHF is characterized by a significant risk of disability and mortality in childhood. The progression of CHF of any etiology is based on the process of cardiovascular remodeling associated with the activation of neurohormonal systems, sympathicoadrenal and renin-angiotensin-aldosterone. Aim of the review: to highlight the issues of the modern view of the etiology, pathogenesis, diagnosis and clinical features in CHF children to increase the knowledge in practitioners for better management of patients. A modern pharmacological treatment method that affects the prognosis and prevents the progression of myocardial damage is based on modulation of the activity of sympathicoadrenal and renin-angiotensin-aldosterone systems at the circulating, tissue, and cellular levels. When determining the treatment of children, the etiology of CHF should be established, concomitant diseases should be identified, the variant and severity of myocardial dysfunction should be determined, and the severity of clinical manifestations should be assessed.
- 27 June 2025
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 28 (3) , 223-230
Open AccessChronic heart failure in children: etiology, pathogenesis, clinical picture and diagnosis
Introduction. Chronic heart failure (CHF) is a threatening complication of cardiovascular diseases or damage in other pathological processes. CHF is characterized by a significant risk of disability and mortality in childhood. The progression of CHF of any etiology is based on the process of cardiovascular remodeling associated with the activation of neurohormonal systems, sympathicoadrenal and renin-angiotensin-aldosterone. Aim of the review: to highlight the issues of the modern view of the etiology, pathogenesis, diagnosis and clinical features in CHF children to increase the knowledge in practitioners for better management of patients. A modern pharmacological treatment method that affects the prognosis and prevents the progression of myocardial damage is based on modulation of the activity of sympathicoadrenal and renin-angiotensin-aldosterone systems at the circulating, tissue, and cellular levels. When determining the treatment of children, the etiology of CHF should be established, concomitant diseases should be identified, the variant and severity of myocardial dysfunction should be determined, and the severity of clinical manifestations should be assessed.
- Open Access
- 16 September 2024
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 27 (4) , 300-308
Generalized infantile arterial calcification in the practice of a pediatric cardiologist
Introduction. Generalized infantile arterial calcification (IAC) is a rare autosomal recessive disease. The diagnosis of IAC is associated with great difficulties due to the variability of clinical manifestations. The high mortality rate in patients at the onset of the disease in early childhood is characterized due to limited possibilities of drug treatment. Aim: to present two clinical reports concerning patients with a genetically verified diagnosis of IAC with long-term catamnestic follow-up (from 2016 to 2023). Results. When coronary vessels are affected with IAC, pronounced ischemic changes are detected on the ECG with confirmed normal anatomy of the coronary arteries, which should alert clinicians and contribute to the inclusion of this form of pathology in the spectrum of differential diagnoses. Conclusion. For the diagnosis of genetically determined IAC, it is extremely important to conduct molecular genetic studies using high-throughput sequencing methods.
- 16 September 2024
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 27 (4) , 300-308
Open AccessGeneralized infantile arterial calcification in the practice of a pediatric cardiologist
Introduction. Generalized infantile arterial calcification (IAC) is a rare autosomal recessive disease. The diagnosis of IAC is associated with great difficulties due to the variability of clinical manifestations. The high mortality rate in patients at the onset of the disease in early childhood is characterized due to limited possibilities of drug treatment. Aim: to present two clinical reports concerning patients with a genetically verified diagnosis of IAC with long-term catamnestic follow-up (from 2016 to 2023). Results. When coronary vessels are affected with IAC, pronounced ischemic changes are detected on the ECG with confirmed normal anatomy of the coronary arteries, which should alert clinicians and contribute to the inclusion of this form of pathology in the spectrum of differential diagnoses. Conclusion. For the diagnosis of genetically determined IAC, it is extremely important to conduct molecular genetic studies using high-throughput sequencing methods.
- 22 February 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (1)
Dynamic observation of nine pediatric patients with Barth syndrome
Barth syndrome (BS) is an orphan disease whose variability of clinical manifestations does not always allow its timely diagnosis, which in its turn reduces the quality of medical care and worsens the prognosis for outcomes. Currently there are some scientific publications in Russia on isolated cases of the disease and none of a kind dedicated to the long-term observation of patients with assessment of the clinical picture. The purpose of this research was to analyze the dynamics of clinical manifestations in children with BS. Materials and methods used: a cohort study included observation of 9 boys with BS in 2015-2022. Results: all patients with genetically confirmed BS were diagnosed with cardiomyopathy with non-compact myocardium, while a dilated remodeling phenotype was noted in 78% of cases. In 67% of children, against the background of complex drug therapy, a decrease in the size of the left ventricle with an increase in ejection fraction was recorded. Neutropenia was detected in 89% of patients, requiring the use of granulocyte colony-stimulating factor in two cases. Frequent detection of prolongation of the QT interval (78%) and ECG patterns simulating the phenomenon of pre-excitation against the background of intraventricular conduction disturbances, acceleration of AV conduction, secondary disturbances of repolarization processes (44%) without fixation of ventricular arrhythmias were noted. The severity of the condition was determined by a combination of severe heart failure, conduction disturbances and clinically significant neutropenia. Fatal outcomes were recorded in 2 children (22%) at the age of 8 months old and 3.5 years old against the background of progressive heart failure and sudden death, respectively. Conclusion: a comprehensive multidisciplinary approach and early diagnosis of BS have an impact on the outcome of the disease.
- 22 February 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (1)
Dynamic observation of nine pediatric patients with Barth syndrome
Barth syndrome (BS) is an orphan disease whose variability of clinical manifestations does not always allow its timely diagnosis, which in its turn reduces the quality of medical care and worsens the prognosis for outcomes. Currently there are some scientific publications in Russia on isolated cases of the disease and none of a kind dedicated to the long-term observation of patients with assessment of the clinical picture. The purpose of this research was to analyze the dynamics of clinical manifestations in children with BS. Materials and methods used: a cohort study included observation of 9 boys with BS in 2015-2022. Results: all patients with genetically confirmed BS were diagnosed with cardiomyopathy with non-compact myocardium, while a dilated remodeling phenotype was noted in 78% of cases. In 67% of children, against the background of complex drug therapy, a decrease in the size of the left ventricle with an increase in ejection fraction was recorded. Neutropenia was detected in 89% of patients, requiring the use of granulocyte colony-stimulating factor in two cases. Frequent detection of prolongation of the QT interval (78%) and ECG patterns simulating the phenomenon of pre-excitation against the background of intraventricular conduction disturbances, acceleration of AV conduction, secondary disturbances of repolarization processes (44%) without fixation of ventricular arrhythmias were noted. The severity of the condition was determined by a combination of severe heart failure, conduction disturbances and clinically significant neutropenia. Fatal outcomes were recorded in 2 children (22%) at the age of 8 months old and 3.5 years old against the background of progressive heart failure and sudden death, respectively. Conclusion: a comprehensive multidisciplinary approach and early diagnosis of BS have an impact on the outcome of the disease.
- Open Access
- 28 December 2023
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 4 (4) , 215-225
Hypertrophic cardiomyopathy and lactic acidosis in a child with acyl-CoA dehydrogenase 9 deficiency. Review of the literature and clinical observation
Introduction. Acyl-CoA dehydrogenase 9 deficiency (mitochondrial complex I deficiency) is an autosomal recessive disease from the heterogeneous group of disorders of mitochondrial β-oxidation of fatty acids caused by mutations in the ACAD9 gene. The disease is characterized by a wide range of clinical manifestations, the most common of which are metabolic acidosis, hypertrophic cardiomyopathy, muscle hypotonicity, and impaired motor skills. The article presents the first Russian clinical observation of a rare variant of hypertrophic cardiomyopathy with early debut in a patient with mitochondrial complex I deficiency caused by homozygous mutation c.659C>T (p.A220V) in the ACAD9 gene and emphasizes the importance of early diagnosis of the disease and complex drug therapy to prevent the development of severe complications. Objective: to describe the clinical course and management of a patient with the pathogenic c.659C>T (p.A220V) variant of the ACAD9 gene. Detailed analysis of anamnesis data, results of clinical, laboratory, instrumental diagnostic methods, and molecular genetic research performed using high-throughput sequencing and direct Sanger sequencing technology. The article presents a literature review and detailed data on clinical observation of a child with homozygous c.659C>T (p.A220V) mutation in the ACAD9 gene diagnosed on the basis of the cardiology department of the National Medical Research Center for Children’s Health. Early disease markers and possibilities of complex drug therapy to prevent the development of severe complications are described. Conclusion. Disruption of mitochondrial beta-oxidation of fatty acids is a heterogeneous group of inherited diseases due to abnormal mitochondrial beta-oxidation and transport of carnitine and fatty acids in mitochondria. A feature of these diseases is the multisystem nature of the lesion and its progressive course. In some cases, the initial clinical manifestations may be various disorders of the cardiovascular system (cardiomyopathy, heart rhythm disturbances), which may cause death in neonatal period and early childhood. Early molecular genetic research provides accurate diagnosis and, accordingly, timely prescription of complex therapy.
- 28 December 2023
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 4 (4) , 215-225
Open AccessHypertrophic cardiomyopathy and lactic acidosis in a child with acyl-CoA dehydrogenase 9 deficiency. Review of the literature and clinical observation
Introduction. Acyl-CoA dehydrogenase 9 deficiency (mitochondrial complex I deficiency) is an autosomal recessive disease from the heterogeneous group of disorders of mitochondrial β-oxidation of fatty acids caused by mutations in the ACAD9 gene. The disease is characterized by a wide range of clinical manifestations, the most common of which are metabolic acidosis, hypertrophic cardiomyopathy, muscle hypotonicity, and impaired motor skills. The article presents the first Russian clinical observation of a rare variant of hypertrophic cardiomyopathy with early debut in a patient with mitochondrial complex I deficiency caused by homozygous mutation c.659C>T (p.A220V) in the ACAD9 gene and emphasizes the importance of early diagnosis of the disease and complex drug therapy to prevent the development of severe complications. Objective: to describe the clinical course and management of a patient with the pathogenic c.659C>T (p.A220V) variant of the ACAD9 gene. Detailed analysis of anamnesis data, results of clinical, laboratory, instrumental diagnostic methods, and molecular genetic research performed using high-throughput sequencing and direct Sanger sequencing technology. The article presents a literature review and detailed data on clinical observation of a child with homozygous c.659C>T (p.A220V) mutation in the ACAD9 gene diagnosed on the basis of the cardiology department of the National Medical Research Center for Children’s Health. Early disease markers and possibilities of complex drug therapy to prevent the development of severe complications are described. Conclusion. Disruption of mitochondrial beta-oxidation of fatty acids is a heterogeneous group of inherited diseases due to abnormal mitochondrial beta-oxidation and transport of carnitine and fatty acids in mitochondria. A feature of these diseases is the multisystem nature of the lesion and its progressive course. In some cases, the initial clinical manifestations may be various disorders of the cardiovascular system (cardiomyopathy, heart rhythm disturbances), which may cause death in neonatal period and early childhood. Early molecular genetic research provides accurate diagnosis and, accordingly, timely prescription of complex therapy.